|
|
 |
|
Viewing report
|
|
|
|
Juvenile Idiopathic Arthritis (JIA): KOL Insights on Treatment Practices and Unmet Needs
Sociable Pharma, Oct 2011, Pages: 116
In-depth primary research was conducted in the US and across Europe with seven key opinion leaders in juvenile idiopathic arthritis (JIA) to understand how therapy use will change in the future. A key theme in this research is the management and implementation of ‘step-up’ treatment strategies to optimize the timing of effective forms of therapy. The view is that this is the major macro-trend that will alter treatment strategy, generating new treatment challenges and presenting opportunities for current and future market players.
Understand key treatment trends including:
- Aggressive versus conservative approaches
- Strategies for treating oligoarthritis, polyarthritis and systemic arthritis
- Long-term patient management on biologic therapies
Identify unmet needs including:
- Managing corticosteroid therapy
- Initiating methotrexate
- Initiating biologic therapy
- Treating sacroiliac juvenile arthritis
- Discontinuing methotrexate and biologics: managing patients with inactive disease
- Treating patients with systemic JIA
Key features:
- 4 treatment maps & 18 treatment settings: A visual guide to the treatment of juvenile idiopathic arthritis, based on extensive primary and secondary research
- Analysis of current US/EU treatment practices involving 7 drug classes: Corticosteroids, synthetic disease-modifying antirheumatic drugs, anti-TNF therapies, anti-interleukins, anti-CD20 antibodies, other biologics and non-steroidal anti-inflammatory drugs
- 9 unmet needs identified: Based on KOL interviews and literature research
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
